文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎基线病毒载量与治疗期间肝癌风险:一项HBeAg阳性患者的多国队列研究

Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
PubMed 文献 · Hepatology · 2024-01-24

该多国队列纳入韩国、香港和台湾的7545例HBeAg阳性、无肝硬化、基线HBV病毒载量≥5.00 log10 IU/mL并启动恩替卡韦或替诺福韦治疗的成人慢性乙型肝炎患者,分析基线病毒载量与治疗期间肝细胞癌风险的关系。中位4.28年治疗期间200例发生肝细胞癌(发生率0.61/100人年),基线HBV DNA与肝细胞癌风险呈非线性独立关联,基线病毒载量≥8.00 log10 IU/mL者风险最低(0.10/100人年),而≥6.00且<7.00 log10 IU/mL者校正后风险为前者的8.05倍(95%CI 3.34-19.35,P<0.001)。

要点

  • HBeAg阳性、无肝硬化、基线HBV DNA≥5.00 log10 IU/mL者启动恩替卡韦或替诺福韦治疗,中位4.28年间肝细胞癌发生率0.61/100人年。
  • 基线HBV DNA与治疗期间肝细胞癌风险呈非线性独立关联,最高基线病毒载量(≥8.00 log10 IU/mL)者风险最低(0.10/100人年)。
  • 基线病毒载量≥6.00且<7.00 log10 IU/mL者校正后肝细胞癌风险为≥8.00 log10 IU/mL者的8.05倍(95%CI 3.34-19.35,P<0.001)。

核心结论

  • 在HBeAg阳性、无肝硬化的成人慢性乙型肝炎多国队列中,尽管接受抗病毒治疗,基线HBV病毒载量仍与肝细胞癌风险显著相关。
  • 基线病毒载量最高并启动治疗的患者长期肝细胞癌发生风险最低。

研究设计与样本

  • 多国队列研究,来自韩国、香港和台湾,纳入7545例HBeAg阳性、无肝硬化、基线HBV病毒载量≥5.00 log10 IU/mL并启动恩替卡韦或替诺福韦治疗的成人慢性乙型肝炎患者。
  • 按基线病毒载量分类分析肝细胞癌风险,中位持续抗病毒治疗4.28年。

主要发现

  • 持续抗病毒治疗期间(中位4.28年)200例发生肝细胞癌,发生率0.61/100人年。
  • 基线HBV DNA水平与治疗期间肝细胞癌风险呈非线性独立关联。
  • 基线病毒载量≥8.00 log10 IU/mL者肝细胞癌风险最低(发生率0.10/100人年),基线病毒载量降低时风险急剧升高。
  • 基线病毒载量≥6.00且<7.00 log10 IU/mL者(发生率1.38/100人年)校正后肝细胞癌风险为基线≥8.00 log10 IU/mL者的8.05倍(95%CI 3.34-19.35,P<0.001)。

关键数值与推荐

  • 基线HBV病毒载量≥8.00 log10 IU/mL:肝细胞癌发生率0.10/100人年。
  • 基线HBV病毒载量≥6.00且<7.00 log10 IU/mL:肝细胞癌发生率1.38/100人年,校正后风险为≥8.00 log10 IU/mL者的8.05倍(95%CI 3.34-19.35,P<0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A single-nation study reported that pretreatment HBV viral load is associated with on-treatment risk of HCC in patients who are HBeAg-positive without cirrhosis and with chronic hepatitis B initiating antiviral treatment. We aimed to validate the association between baseline HBV viral load and on-treatment HCC risk in a larger, multinational cohort. APPROACH AND RESULTS: Using a multinational cohort from Korea, Hong Kong, and Taiwan involving 7545 adult patients with HBeAg-positive, without cirrhosis and with chronic hepatitis B who started entecavir or tenofovir treatment with baseline HBV viral load ≥5.00 log 10 IU/mL, HCC risk was estimated by baseline viral load. HBV viral load was analyzed as a categorical variable. During continuous antiviral treatment (median, 4.28 y), HCC developed in 200 patients (incidence rate, 0.61 per 100 person-years). Baseline HBV DNA level was independently associated with on-treatment HCC risk in a nonlinear pattern. HCC risk was lowest with the highest baseline viral load (≥8.00 log 10 IU/mL; incidence rate, 0.10 per 100 person-years), but increased sharply as baseline viral load decreased. The adjusted HCC risk was 8.05 times higher (95% CI, 3.34-19.35) with baseline viral load ≥6.00 and <7.00 log 10 IU/mL (incidence rate, 1.38 per 100 person-years) compared with high (≥8.00 log 10 IU/mL) baseline viral load ( p <0.001). CONCLUSIONS: In a multinational cohort of adult patients with HBeAg-positive without cirrhosis and with chronic hepatitis B, baseline HBV viral load was significantly associated with HCC risk despite antiviral treatment. Patients with the highest viral load who initiated treatment had the lowest long-term risk of HCC development.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Choi WM, Yip TC, Kim WR, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients. Hepatology. 2024. PMID: 38436992. doi:10.1097/HEP.0000000000000752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。